Tigermed Plans Overseas Laboratory Business Divestment to Focus on Core Clinical CRO Operations

• Hangzhou Tigermed agreed on November 9, 2026, to divest its overseas laboratory services business through Frontage Holdings’ privatization and subsequent separation.
• The reorganization will leave CRL owning 100% of Frontage Holdings; Tigermed will retain Frontage International and its subsidiaries.
• The divestment supports a sharper focus on its core clinical CRO business in China.
• Expected gains total at least approximately RMB 500 million; cash consideration for cancellation of the Company Scheme Shares is HKD 535.67 million.
• The privatization offers HKD 2.37 per Scheme Share, subject to shareholder approval and other closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Tigermed Consulting Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261109-12406109), on November 09, 2026, and is solely responsible for the information contained therein.